Page 133 - 《中国药房》2020年22期

[37] HIGASHIMORI A，WATANABE T，NADATANI Y，et al. [52] ALRAFAS HR，BUSBEE PB，NAGARKATTI M，et al.
Mechanisms of NLRP3 inflammasome activation and its Resveratrol downregulates miR-31 to promote t regulato-
role in NSAID-induced enteropathy[J]. Mucosal Immunol， ry cells during prevention of TNBS-induced colitis[J].
2016，9（3）：659-668. Mol Nutr Food Res，2020. DOI：10.1002/mnfr.201900633.
[38] PLOGER S，STUMPFF F，PENNER GB，et al. Microbial [53] MATIJASIC M，MESTROVIC T，PERIC M，et al. Modu-
butyrate and its role for barrier function in the gastrointes- lating composition and metabolic activity of the gut micro-
tinal tract[J]. Ann N Y Acad Sci，2012. DOI：10.1111/ biota in IBD patients[J]. Int J Mol Sci，2016. DOI：10.3390/
j.1749-6632.2012.06553.x. ijms17040578.
[39] LUHRS H，GERKE T，MULLER JG，et al. Butyrate inhib- [54] AOYAMA M，KOTANI J，USAMI M. Butyrate and propi-
its NF-kappaB activation in lamina propria macrophages onate induced activated or non-activated neutrophil apop-
of patients with ulcerative colitis[J]. Scand J Gastroenter- tosis via HDAC inhibitor activity but without activating
ol，2002，37（4）：458-466. GPR-41/GPR-43 pathways[J]. Nutrition，2010，26（6）：
[40] LE BOURHIS L，BENKO S，GIRARDIN SE. Nod1 and 653-661.
Nod2 in innate immunity and human inflammatory disor- [55] BHAT MI，KAPILA R. Dietary metabolites derived from
ders[J]. Biochem Soc Trans，2007，35（6）：1479-1484. gut microbiota：critical modulators of epigenetic changes
[41] HINNEBUSCH BF，HENDERSON JW，SIDDIQUE A， in mammals[J]. Nutr Rev，2017，75（5）：374-389.
et al. Transcriptional activation of the enterocyte differenti- [56] SOKOL H. Probiotics and antibiotics in IBD[J]. Dig Dis，
2015，32（S1）：10-17.
ation marker intestinal alkaline phosphatase is associated
with changes in the acetylation state of histone H3 at a [57] KHAN KJ，ULLMAN TA，FORD AC，et al. Antibiotic
specific site within its promoter region in vitro[J]. J Gas- therapy in inflammatory bowel disease：a systematic re-
view and meta-analysis[J]. Am J Gastroenterol，2011，106
trointest Surg，2003，7（2）：237-244.
（4）：661-673.
[42] PAULEY KM，CHAN EK. MicroRNAs and their emerg-
[58] KATO K，MIZUNO S，UMESAKI Y，et al. Randomized
ing roles in immunology[J]. Ann N Y Acad Sci，2008.
placebo-controlled trial assessing the effect of bifidobacte-
DOI：10.1196/annals.1443.009.
ria-fermented milk on active ulcerative colitis[J]. Aliment
[43] BARTEL DP. MicroRNAs：genomics，biogenesis，mecha-
Pharmacol Ther，2004，20（10）：1133-1141.
nism，and function[J]. Cell，2004，116（2）：281-297.
[44] WU F，ZIKUSOKA M，TRINDADE A，et al. MicroRNAs [59] DO VT，BAIRD BG，KOCKLER DR. Probiotics for main-
taining remission of ulcerative colitis in adults[J]. Ann
are differentially expressed in ulcerative colitis and alter
Pharmacother，2010，44（3）：565-571.
expression of macrophage inflammatory peptide-2 al-
[60] GUSLANDI M. Saccharomyces boulardii plus rifaximin
pha[J]. Gastroenterology，2008，135（5）：1624-1635.
in mesalamine-intolerant ulcerative colitis[J]. J Clin Gas-
[45] CHEN WX，REN LH，SHI RH. Implication of miRNAs
troenterol，2010. DOI：10.1097/MCG.ob013e3181cb4233.
for inflammatory bowel disease treatment：systematic re-
[61] MALDONADO-GOMEZ MX，MARTINEZ I，BOTTACI-
view[J]. World J Gastrointest Pathophysiol，2014，5（2）：
NI F，et al. Stable engraftment of bifidobacterium longum
63-70. AH1206 in the human gut depends on individualized fea-
[46] 周鹏志，陈斌，胡品津，等. miR-19a对溃疡性结肠炎的作
tures of the resident microbiome[J]. Cell Host Microbe，
用机制[J].南方医科大学学报，2013，33（9）：1325-1328.
2016，20（4）：515-526.
[47] ZHANG Y，WANG Z，GEMEINHART RA. Progress in
[62] KHORUTS A，DICKSVED J，JANSSON JK，et al. Chang-
microRNA delivery[J]. J Control Release，2013，172（3）：
es in the composition of the human fecal microbiome after
962-974. bacteriotherapy for recurrent Clostridium difficile-associ-
[48] IBRAHIM AF，WEIRAUCH U，THOMAS M，et al. Mi- ated diarrhea[J]. J Clin Gastroenterol，2010，44（5）：354-
croRNA replacement therapy for miR-145 and miR-33a is 360.
efficacious in a model of colon carcinoma[J]. Cancer Res， [63] DUVALLET C，ZELLMER C，PANCHAL P，et al. Frame-
2011，71（15）：5214-5224. work for rational donor selection in fecal microbiota trans-
[49] THOMAS M，LANGE-GRUNWELLER K，WEIRAUCH plant clinical trials[J]. PLoS One，2019. DOI：10.1371/
U，et al. The proto-oncogene Pim-1 is a target of miR- journal.pone.0222881.
33a[J]. Oncogene，2012，31（7）：918-928. [64] WANG ZK，YANG YS，CHEN Y，et al. Intestinal microbi-
[50] 毕秀丽，吴春福，赵余庆，等.美国黑树莓的肿瘤预防生物 ota pathogenesis and fecal microbiota transplantation for
活性研究进展[J].中草药，2012，43（11）：2295-2299. inflammatory bowel disease[J]. World J Gastroenterol，
[51] 郭君，毛丽萍，李倩倩，等.黑树莓花青素靶向调控 miR- 2014，20（40）：14805-14820.
338-5p/SIRT1 相关信号通路对结直肠癌的化学预防作 （收稿日期：2020-07-07 修回日期：2020-10-22）
用[J].中草药，2018，49（4）：853-858. （编辑：孙 冰）

中国药房 2020年第31卷第22期 China Pharmacy 2020 Vol. 31 No. 22 ·2811 ·